EM2P2, Inc. is the creator of CannaLnx™, the leading digital health platform linking the world of cannabis medicine—and digitizing the medical-cannabis recommendation/certification and fulfillment processes. CannaLnx’s end-to-end platform is new in the market. The product/SaaS-service brand “CannaLnx” derives from “cannabis” and the system’s features “linking” industry participants. EM2P2’s CannaLnx online SaaS platform is a HIPAA-compliant registry/tracking software tool (patent pending) for use by medical-cannabis recommending/certifying medical professionals, patients, dispensaries, growers, processors, and test labs. It is a comprehensive communication, transaction-processing, and reporting platform for all medical-cannabis program participants. It enables and secures effective communication among all program participants, streamlines state-mandated transaction reporting requirements, and is a reliable data hub for the industry, regulators, and researchers. The system links users on the consumer side (patients and doctors), the commercial side (dispensaries, growers, processors, and test labs), and the governance side (state governing agencies, regulators, educators, researchers). CannaLnx expects to facilitate delivery of ten million new patients into the medical-cannabis industry by 2020, in part through its unique industry liaisons and exclusive alliances with The American Society of Cannabis Medicine, the CannaScripts medical-cannabis group-saving discount program, and the Committee for Responsible Cannabis (CFRC) and the American Council of Cannabis Medicine (ACCM), both Washington DC based nonprofits dedicated to medical-cannabis advocacy.